Please assess the completion status of the following clinical trial:

Trial Title: Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3, 2018.~* Age of the participant at the time of migraine onset \< 50 years -History of 4 to 14 migraine days per month on average in the 3 months prior to Visit 1 in the investigator's judgment~* Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period. Male participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period.~* 4 to 14 migraine days in the 28-day baseline period per eDiary~* Failed oral migraine prophylaxis medications from 2 to 4 medication classes~Exclusion Criteria:~* Any clinically significant hematologic, endocrine, pulmonary, hepatic, gastrointestinal, or neurologic disease~* Participant has any other concurrent pain condition that, in the opinion of the investigator, may significantly impact the current headache disorder~* In the opinion of the investigator, confounding psychiatric conditions, dementia, epilepsy, or significant neurological disorders other than migraine~* Has ≥ 15 headache days per month on average across the 3 months prior to Visit 1 in the investigator's judgment~* Has ≥ 15 headache days in the 28-day baseline period per eDiary~* Clinically significant cardiovascular or cerebrovascular disease~* Has a history of migraine accompanied by diplopia or decreased level of consciousness or retinal migraine as defined by ICHD-3, 2018~* Has a current diagnosis of chronic migraine, new persistent daily headache, medication overuse headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3, 2018

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received atogepant-matching placebo tablets, orally, once daily (QD) for up to 12 weeks in a double-blind (DB) treatment period.
- Atogepant 60 mg (Type: ACTIVE_COMPARATOR): Participants received atogepant 60 mg, orally, QD for up to 12 weeks in a DB treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).